Advertisement

Association between serum levels of hepcidin and ferritin in patients with thalassemia major and intermedia, the role of iron chelator

  • Seyed Kamal Eshagh Hossaini
  • Mohammad reza HaeriEmail author
Original Article
  • 7 Downloads

Abstract

Patients with beta-thalassemia suffer from iron overload, and hepcidin, as the main regulator of iron hemostasis, can indicate iron overload better than serum ferritin, but changes in serum hepcidin levels are affected by the type of thalassemia (major or intermediate) and by type of treatments. The present study aimed to determine the correlation between serum levels of hepcidin and ferritin in patients with thalassemia major and intermedia under chelation therapy. This cohort study investigated 143 patients with thalassemia (122 patients with thalassemia major and 21 patients with and thalassemia intermedia) who referred to Thalassemia Center of Qom University of Medical Sciences, Qom, Iran. The serum level of ferritin was measured twice in all patients: in the beginning and after taking iron chelator by ECL method. Hepcidin was assayed at the end of the study by ELISA methods. Demographic data and clinical history of the patients (type of disease, type of drugs used, and blood transfusion history) were completely recorded. The mean serum level of hepcidin in the TM group (2249.62 ± 1547.37 ng/ml) was greater than the TI group (1482.43 ± 1314.26 ng/ml) (p = 0.007). However, there was no meaningful difference in serum ferritin level between the two groups (2997.74 ± 2545.66 vs. 2670.62 ± 2670.04 ng/ml, p > 0.05). Serum ferritin and hepcidin levels were not correlated both in TM or TI patients (p > 0.05). However, evaluating the trend of changes in serum levels of ferritin with hepcidin showed a significant association. High serum levels of ferritin indicated high iron overload in both groups, TM and TI, which decreased after treatment with chelators. The higher hepcidin levels in TM patients in comparison to TI patients could reflect the higher iron overload in these patients. However, further cellular studies are needed to evaluate the accuracy of these tests in the assessment of iron overload.

Keywords

Hepcidin Ferritin Beta-thalassemia 

Notes

Acknowledgments

The authors of the present study sincerely thank Miss Farhadi for technical assistance.

Compliance with ethical standards

Conflict of interest

The authors declare that there is no conflict of interest.

References

  1. 1.
    Cao A, Galanello R (2010) Beta-thalassemia. Genet Med 12(2):61–68CrossRefGoogle Scholar
  2. 2.
    Muncie HL Jr, Campbell J (2009) Alpha and beta thalassemia. Am Fam Physician 80(4):339–344Google Scholar
  3. 3.
    Weatherall DJ (2008) Hemoglobinopathies worldwide: present and future. Curr Mol Med 8(7):592–599CrossRefGoogle Scholar
  4. 4.
    Samavat A, Modell B (2004) Iranian national thalassemia screening program. BMJ 329(7475):1134–1137CrossRefGoogle Scholar
  5. 5.
    Fallah MS, Samavat A, Zeinali S (2009) Iranian national program for the prevention of thalassemia and prenatal diagnosis: mandatory premarital screening and legal medical abortion. Prenat Diagn 29(13):1285–1286CrossRefGoogle Scholar
  6. 6.
    Saffi M, Howard N (2015) Exploring the effectiveness of mandatory premarital screening and genetic counselling programmes for beta-thalassaemia in the Middle East: a scoping review. Public Health Genomics 18(4):193–203CrossRefGoogle Scholar
  7. 7.
    Rund D, Rachmilewitz E (2005) β-Thalassemia. N Engl J Med 353(11):1135–1146CrossRefGoogle Scholar
  8. 8.
    Ozment CP, Turi JL (2009) Iron overload following red blood cell transfusion and its impact on disease severity. Biochim Biophys Acta 1790(7):694–701CrossRefGoogle Scholar
  9. 9.
    Ashayeri N, Sadeghi E, Sadeghi S, Eshghi P, Alavi S (2016) Efficacy of Deferasirox (Exjade®) versus Osveral® in treatment of Iron overload in patients with Beta-thalassemia major in Iran; a non-randomized controlled trial. Iran J Blood Cancer 8(4):103–107Google Scholar
  10. 10.
    Taher AT, Porter J, Viprakasit V, Kattamis A, Chuncharunee S, Sutcharitchan P, Siritanaratkul N, Galanello R, Karakas Z, Lawniczek T, Ros J, Zhang Y, Habr D, Cappellini MD (2012) Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study. Blood. 120(5):970–977CrossRefGoogle Scholar
  11. 11.
    Gardenghi S, Marongiu MF, Ramos P, Guy E, Breda L, Chadburn A, Liu Y, Amariglio N, Rechavi G, Rachmilewitz EA, Breuer W, Cabantchik ZI, Wrighting DM, Andrews NC, de Sousa M, Giardina PJ, Grady RW, Rivella S (2007) Ineffective erythropoiesis in beta-thalassemia is characterized by increased iron absorption mediated by down-regulation of hepcidin and up-regulation of ferroportin. Blood. 109(11):5027–5035CrossRefGoogle Scholar
  12. 12.
    Nemeth E, Ganz T (2006) Regulation of iron metabolism by hepcidin. Annu Rev Nutr 26:323–342CrossRefGoogle Scholar
  13. 13.
    De Franceschi L, Daraio F, Filippini A, Carturan S, Muchitsch EM, Roetto A et al (2006) Liver expression of hepcidin and other iron genes in two mouse models of beta-thalassemia. Haematologica. 91(10):1336–1342Google Scholar
  14. 14.
    Kaddah AM, Abdel-Salam A, Farhan MS, Ragab R (2017) Serum hepcidin as a diagnostic marker of severe iron overload in beta-thalassemia major. Indian J Pediatr 84(10):745–750CrossRefGoogle Scholar
  15. 15.
    Origa R, Galanello R, Ganz T, Giagu N, Maccioni L, Faa G, Nemeth E (2007) Liver iron concentrations and urinary hepcidin in beta-thalassemia. Haematologica. 92(5):583–588CrossRefGoogle Scholar
  16. 16.
    Britton RS, Leicester KL, Bacon BR (2002) Iron toxicity and chelation therapy. Int J Hematol 76(3):219–228CrossRefGoogle Scholar
  17. 17.
    Wessling-Resnick M (2010) Iron homeostasis and the inflammatory response. Annu Rev Nutr 30:105–122CrossRefGoogle Scholar
  18. 18.
    Melchiori L, Gardenghi S, Rivella S (2010) beta-Thalassemia: HiJAKing ineffective erythropoiesis and iron overload. Adv Hematol 2010:938640CrossRefGoogle Scholar
  19. 19.
    Ganz T, Nemeth E (2012) Hepcidin and iron homeostasis. Biochim Biophys Acta 1823(9):1434–1443CrossRefGoogle Scholar
  20. 20.
    Tanno T, Bhanu NV, Oneal PA, Goh SH, Staker P, Lee YT, Moroney JW, Reed CH, Luban NLC, Wang RH, Eling TE, Childs R, Ganz T, Leitman SF, Fucharoen S, Miller JL (2007) High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med 13(9):1096–1101CrossRefGoogle Scholar
  21. 21.
    Haghpanah S, Esmaeilzadeh M, Honar N, Hassani F, Dehbozorgian J, Rezaei N, Abdollahi M, Bardestani M, Safaei S, Karimi M (2015) Relationship between serum hepcidin and ferritin levels in patients with thalassemia major and intermedia in southern Iran. Iran Red Crescent Med J 17(7):e28343Google Scholar
  22. 22.
    Kattamis A, Papassotiriou I, Palaiologou D, Apostolakou F, Galani A, Ladis V, Sakellaropoulos N, Papanikolaou G (2006) The effects of erythropoietic activity and iron burden on hepcidin expression in patients with thalassemia major. Haematologica. 91(6):809–812Google Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Seyed Kamal Eshagh Hossaini
    • 1
  • Mohammad reza Haeri
    • 2
    Email author
  1. 1.Departmennt of Pediatrics, Faculty of MedicineQom University of Medical SciencesQomIran
  2. 2.Depatment of Clinical Biochemistry, Faculty of MedicineQom University of Medical SciencesQomIran

Personalised recommendations